Sequential compression biomechanical device versus primary amputation in patients with critical limb ischemia

Area of Science:

• Vascular Surgery
• Medical Devices
• Regenerative Medicine

Background:

• Critical Limb Ischemia (CLI) poses a significant risk of amputation for patients ineligible for revascularization.
• Sequential Compression Biomechanical Device (SCBD) therapy presents a limb salvage alternative.

Purpose of the Study:

• To evaluate the efficacy of SCBD in severe CLI patients who cannot undergo revascularization.
• Primary endpoints included limb salvage and 30-day mortality rates.

Main Methods:

• A cohort of 189 patients with severe CLI, unsuitable for revascularization, was studied between 2005 and 2012.
• 171 patients underwent SCBD therapy, compared against 75 matched patients who had primary amputations.

Main Results:

• Sustained clinical improvement was observed in 68% of patients at 1 year.
• Significant increases in mean toe pressure (19.9 to 35.42 mm Hg) and popliteal flow (35.44 to 55.91 cm/sec) were noted (P < .0001).
• Limb salvage reached 94% at 5 years, with a 30-day mortality of only 0.6%. SCBD therapy was substantially more cost-effective than primary amputation.

Conclusions:

• SCBD therapy is a clinically effective and cost-efficient treatment for CLI patients lacking revascularization options.
• It achieves significant limb salvage and pain relief without invasive procedures.